Cross-Vendor Testing of HM-MRI

MVP2 was successfully implemented and tested to measure prostate tissue composition non-invasively from multiple MRI vendors.

Tested at multiple centers and multiple scanners

Philips 3T Achievaand Ingenia (UChicago) using endorectalcoil

SiemensSkyra3T (Ingalls Memorial Hospital, Flossmoor, IL) without endorectalcoil

HM-MRI metrics (tissue composition) were very similar for Philips and Siemens scanners and similar to those reported in literature.

Protocol validated using endorectalcoil or without it.  

Cancer is characterized by increased epithelium and reduced lumen in both cohorts with similar diagnostic accuracy (ROC analysis) for diagnosing cancer on Philips (AUC = 0.94-0.99),Siemens (AUC = 0.83-0.98).

We are currently validating HM-MRI on GEscanners.